Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Catalyst Biosciences is a biotechnology business based in the US. Catalyst Biosciences shares (CBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Biosciences employs 45 staff and has a trailing 12-month revenue of around $3.2 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $0.30 |
|---|---|
| 52-week range | $0.20 - $1.29 |
| 50-day moving average | $0.51 |
| 200-day moving average | $0.43 |
| Wall St. target price | $16.00 |
| PE ratio | 0.72 |
| Dividend yield | $1.43 (0%) |
| Earnings per share (TTM) | $0.42 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.3 from 2023-01-27
| 1 week (2023-01-23) | 11.11% |
|---|---|
| 1 month (2022-12-30) | -43.40% |
| 3 months (2022-10-28) | -48.35% |
| 6 months (2022-07-29) | -82.86% |
| 1 year (2022-01-26) | N/A |
|---|---|
| 2 years (2021-01-29) | -94.69% |
| 3 years (2020-01-30) | 7.51 |
| 5 years (2018-01-30) | 42.54 |
Valuing Catalyst Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalyst Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Catalyst Biosciences shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Catalyst Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalyst Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $3.2 million |
|---|---|
| Gross profit TTM | $-64,906,000 |
| Return on assets TTM | -46.47% |
| Return on equity TTM | 26.37% |
| Profit margin | 367.44% |
| Book value | $0.93 |
| Market capitalisation | $11.4 million |
TTM: trailing 12 months
Dividend payout ratio: 4.39% of net profits
Recently Catalyst Biosciences has paid out, on average, around 4.39% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Catalyst Biosciences shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Catalyst Biosciences's case, that would currently equate to about $1.43 per share.
While Catalyst Biosciences's payout ratio might seem low, this can signify that Catalyst Biosciences is investing more in its future growth.
Catalyst Biosciences's most recent dividend payout was on 11 January 2023. The latest dividend was paid out to all shareholders who bought their shares by 12 January 2023 (the "ex-dividend date").
Catalyst Biosciences's shares were split on a 1:15 basis on 12 February 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Catalyst Biosciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Catalyst Biosciences shares which in turn could have impacted Catalyst Biosciences's share price.
Over the last 12 months, Catalyst Biosciences's shares have ranged in value from as little as $0.2 up to $1.2939. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Biosciences's is 1.3757. This would suggest that Catalyst Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc. ; and license and collaboration agreement with Biogen International GmbH.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
